Cargando…

Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy

Detalles Bibliográficos
Autor principal:	Taddei-Allen, Patty
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2022
Materias:	Perspectives on Value
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372992/ https://www.ncbi.nlm.nih.gov/pubmed/35199579 http://dx.doi.org/10.18553/jmcp.2022.28.3.376

Ejemplares similares

Mavacamten for hypertrophic cardiomyopathy: effectiveness and value: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Beinfeld, Molly, et al.
Publicado: (2022)

Importance of Patient-Centered Outcomes When Evaluating Treatments for Secondary Progressive Multiple Sclerosis
por: Taddei-Allen, Patty
Publicado: (2020)

Shifting paradigms: Reframing coverage of antiobesity medications for plan sponsors
por: Green, Libbi, et al.
Publicado: (2023)

Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions
por: Dong, Tiffany, et al.
Publicado: (2023)

Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy
por: Scholtz, Smita, et al.
Publicado: (2023)

Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten
por: Mathai, Susan, et al.
Publicado: (2022)

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)

Evolution of the Pharmacy Benefit Manager/Community Pharmacy Relationship: An Opportunity for Success
por: Taddei-Allen, Patty
Publicado: (2020)

The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review
por: Edelberg, Jay M., et al.
Publicado: (2022)

Managing high-priced biologic agents: challenges and potential solutions
por: Li, Meng, et al.
Publicado: (2021)

The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients
por: DeVries, J Hans, et al.
Publicado: (2023)

Emerging treatments for lupus nephritis: health equity considerations in clinical research and coverage
por: Newman, Terri V, et al.
Publicado: (2021)

Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial
por: Tian, Zhuang, et al.
Publicado: (2023)

Efficacy and safety of mavacamten in treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis
por: Memon, Areeba, et al.
Publicado: (2023)

Analyzing safety and effectiveness of Mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis
por: Rangwala, Hussain Sohail, et al.
Publicado: (2023)

The effectiveness and value of novel treatments for cystic fibrosis: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A, et al.
Publicado: (2021)

Medications for obesity management: Effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Atlas, Steven J, et al.
Publicado: (2023)

The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

The effectiveness and value of novel acute treatments for migraine: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

The effectiveness and value of betibeglogene autotemcel for the management of transfusion-dependent beta-thalassemia: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Lancaster, Victoria, et al.
Publicado: (2022)

The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021)

The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials
por: Rabiee Rad, Mehrdad, et al.
Publicado: (2023)

424 Considerations Mid-Translation of a Novel Extracellular Vesicle Product in Myocarditis
por: Beetler, Danielle, et al.
Publicado: (2022)

The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Synnott, Patricia G., et al.
Publicado: (2020)

The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Wright, Abigail C, et al.
Publicado: (2023)

Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: McKenna, Avery, et al.
Publicado: (2023)

The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A, et al.
Publicado: (2023)

The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Nikitin, Dmitriy, et al.
Publicado: (2023)

The potential promise and challenge for tezepelumab as a biologic therapy for severe asthma
por: Williams, Dennis M
Publicado: (2022)

The effectiveness and value of tirzepatide for type 2 diabetes mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Nikitin, Dmitriy, et al.
Publicado: (2022)

The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2022)

The ICER review is in: hope amidst uncertainty
por: Begolka, Wendy Smith, et al.
Publicado: (2022)

From access to equity: The devil is in “Z” details
por: Schulte, Adam, et al.
Publicado: (2022)

The effectiveness and value of tezepelumab for severe asthma: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Rind, David M, et al.
Publicado: (2022)

JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2022)

Oral treatments for outpatient COVID-19: Effectiveness and value: A Summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2022)

The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2021)

Evaluating a Stone of Hope: ICER’s 2019 Review of Treatments for Duchenne Muscular Dystrophy
por: Brandsema, John Frederick
Publicado: (2020)

ICER report on Alzheimer’s disease: implications from a patient perspective
por: Franklin, Meg
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0tdt3jiep1vis17ncp6hcv9lkh